Johnson & Johnson's $5.5 billion settlement may be a record payout, but it lets the company off the hook without admitting wrongdoing. For victims and consumer advocates, this is a missed opportunity to hold J&J fully accountable. The settlement allows J&J to avoid a public trial where internal memos and emails could have revealed what executives knew about asbestos risks in talc.
The amount, while large, may be inadequate. Thousands of claimants share the pool, and legal fees will consume a portion. Individual plaintiffs with severe mesothelioma or advanced ovarian cancer might receive only modest sums—far less than punitive damages a jury might have awarded. Moreover, the settlement does not prevent future lawsuits, as J&J continues to face new cases filed after the cutoff.
Critics also point to J&J's long history of denying allegations. By settling without admission, the company sidesteps any regulatory or criminal consequences. The US Department of Justice had investigated but closed the case without charges. This settlement could be seen as a way to buy silence and bury evidence of potential negligence.
For Indian consumers, the case raises questions about global product safety standards. J&J continues to sell talc-based baby powder in some markets, though it has phased it out in the US and Canada. The settlement might not prompt stronger regulations in countries with weaker consumer protections. Activists argue that companies should face trials to establish fault, set precedents, and deter future harm.
In the end, the settlement is a financial transaction, not a verdict. It provides money for victims but leaves key questions unanswered—whether the product was truly safe and whether J&J's actions were ethical. Without a legal finding of liability, the company may continue with business as usual, leaving public trust unresolved.